Jefferies Financial Group reaffirmed their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Friday morning. Jefferies Financial Group currently has a GBX 1,580 ($20.65) target price on the stock.
GSK has been the subject of a number of other reports. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline in a research report on Tuesday, August 21st. Berenberg Bank reaffirmed a buy rating and issued a GBX 1,790 ($23.39) target price on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Liberum Capital lowered GlaxoSmithKline from a buy rating to a hold rating and boosted their target price for the company from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research report on Thursday, August 30th. Barclays reaffirmed an overweight rating on shares of GlaxoSmithKline in a research report on Friday, August 10th. Finally, Citigroup boosted their target price on GlaxoSmithKline from GBX 1,400 ($18.29) to GBX 1,600 ($20.91) and gave the company a neutral rating in a research report on Friday, July 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of GBX 1,533.55 ($20.04).
Shares of GSK stock traded down GBX 22.20 ($0.29) during mid-day trading on Friday, hitting GBX 1,429.40 ($18.68). The company’s stock had a trading volume of 12,405,381 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).
In related news, insider Philip R. Hampton acquired 2,810 shares of the firm’s stock in a transaction on Wednesday, July 25th. The stock was purchased at an average cost of GBX 1,557 ($20.34) per share, with a total value of £43,751.70 ($57,169.35). Also, insider David Redfern sold 1,925 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.58), for a total value of £30,318.75 ($39,616.82). Insiders have acquired a total of 2,835 shares of company stock valued at $4,413,165 over the last three months.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: NASDAQ Stock Market Explained
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.